SCHEMBL29355244

SCHEMBL29355244

C[C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
PTGS2 P35354 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ECE1 P42892 1/20 0.44
MME P08473 2/20 0.43
ACE P12821 2/20 0.43
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
DPP4 P27487 1/20 0.41
PTGS1 P23219 1/20 0.38
GSTK1 Q9Y2Q3 1/20 0.38
OPRD1 P41143 5/20 0.37
OPRM1 P35372 4/20 0.37
OPRK1 P41145 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
CTRB1 P17538 3/20 0.36
GLO1 Q04760 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589671 1.00 ALDH1A1 (0.50) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL2544527 0.98 ALDH1A1 (0.52) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL11253834 0.98 ALDH1A1 (0.52) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL32680129 0.93 ALDH1A1 (0.44) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585206 0.91 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585205 0.91 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30585204 0.91 ALDH1A1 (0.46) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL30637048 0.89 ALDH1A1 (0.43) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29906328 0.86 EGFR (0.42) ALDH1A1LMNAMAPTPTGS2TDP1
SCHEMBL29454351 0.86 ALDH1A1 (0.47) ALDH1A1LMNAMAPTPTGS2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124212-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN INC (US) 2026-05-07 US disclosed
US-12390471-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof IMMUNOGEN, INC. (US) 2025-08-19 US disclosed
CN-116785450-A Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-09-22 CN disclosed
CN-116785451-A Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-09-22 CN disclosed
CN-110366431-B Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof 伊缪诺金公司 2023-07-18 CN disclosed
US-20220133711-A1 CAMPTOTHECIN DERIVATIVES IMMUNOGEN, INC. 2022-05-05 US disclosed
US-20220111067-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF IMMUNOGEN SWITZERLAND GMBH (CH) 2022-04-14 US disclosed
US-11229639-B2 Camptothecin derivatives IMMUNOGEN, INC. (US) 2022-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390471-B2 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof VIP, AREG, MIF ALDH1A1 1927/4885LMNA 3531/4885MAPT 3556/4885
US-20220111067-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VIP, AREG, MIF ALDH1A1 1927/4885LMNA 3531/4885MAPT 3556/4885
US-20220133711-A1 CAMPTOTHECIN DERIVATIVES TOP2A, TOP2B, PCNA ALDH1A1 1182/4885LMNA 2121/4885MAPT 3921/4885
US-20260124212-A1 MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF VEGFA, VIP, AREG ALDH1A1 2585/4885LMNA 1078/4885MAPT 4002/4885
US-11229639-B2 Camptothecin derivatives TOP2A, TOP2B, PCNA ALDH1A1 1182/4885LMNA 2121/4885MAPT 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.